Cargando…

Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran

INTRODUCTION: Patient registries play an important role in obtaining real-world evidence of the cost-effectiveness of treatments. However, their implementation is costly and sometimes infeasible in many middle-income countries (MICs). We explored the combination of data-mining and a large claims dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansaripour, Amir, Zendehdel, Kazem, Tadayon, Niki, Sadeghi, Fatemeh, Uyl-de Groot, Carin A., Redekop, W. Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166984/
https://www.ncbi.nlm.nih.gov/pubmed/30273393
http://dx.doi.org/10.1371/journal.pone.0205079
_version_ 1783360124915548160
author Ansaripour, Amir
Zendehdel, Kazem
Tadayon, Niki
Sadeghi, Fatemeh
Uyl-de Groot, Carin A.
Redekop, W. Ken
author_facet Ansaripour, Amir
Zendehdel, Kazem
Tadayon, Niki
Sadeghi, Fatemeh
Uyl-de Groot, Carin A.
Redekop, W. Ken
author_sort Ansaripour, Amir
collection PubMed
description INTRODUCTION: Patient registries play an important role in obtaining real-world evidence of the cost-effectiveness of treatments. However, their implementation is costly and sometimes infeasible in many middle-income countries (MICs). We explored the combination of data-mining and a large claims database to estimate the direct healthcare costs of HER2-positive breast cancer (BC) treatment in Iran and the fraction of total costs from trastuzumab use. METHOD: We performed a retrospective analysis of claims data from the Iran Social Security Organization, a health insurer which covers approximately 50%(~40 million) of the Iranian population, in the period of 21/03/2011-20/03/2014. A data-mining algorithm using R software and validated using patient dossiers in the Cancer Research Center identified 1295 patients and divided them into the three main HER2-positive breast cancer stages (early, loco-regional and advanced). A payer perspective was used to calculate the absolute and relative direct costs of healthcare services associated with the treatment of HER2-positive breast cancer in the public and private healthcare systems. RESULTS: The number of women totaled 802 (early), 125 (loco-regional) and 218 (advanced). The mean age[SD] was 45[10], 46[10] and 48[10] years, respectively, while mean follow-up in all stages was approximately one year. Average costs of direct healthcare care in early, loco-regional and advanced stages were €11,796 (95%CI: €9,356-€12,498), €8,253 (95%CI: €6,843-€10,002), and €17,742 (95%CI: €15,720-€19,505), respectively. Trastuzumab accounted for the largest share of total costs in all three stages (range: 53–76%). CONCLUSION: Wherever comprehensive patient registries are infeasible or costly, real-world costs can be estimated through claims databases and data-mining strategies. Using this method, real-world costs have been estimated in Iran. The stage-specific cost estimates derived from this study can be used to perform real-world cost-effectiveness analyses of therapies for HER2-positive BC and support healthcare financing decisions.
format Online
Article
Text
id pubmed-6166984
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-61669842018-10-19 Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran Ansaripour, Amir Zendehdel, Kazem Tadayon, Niki Sadeghi, Fatemeh Uyl-de Groot, Carin A. Redekop, W. Ken PLoS One Research Article INTRODUCTION: Patient registries play an important role in obtaining real-world evidence of the cost-effectiveness of treatments. However, their implementation is costly and sometimes infeasible in many middle-income countries (MICs). We explored the combination of data-mining and a large claims database to estimate the direct healthcare costs of HER2-positive breast cancer (BC) treatment in Iran and the fraction of total costs from trastuzumab use. METHOD: We performed a retrospective analysis of claims data from the Iran Social Security Organization, a health insurer which covers approximately 50%(~40 million) of the Iranian population, in the period of 21/03/2011-20/03/2014. A data-mining algorithm using R software and validated using patient dossiers in the Cancer Research Center identified 1295 patients and divided them into the three main HER2-positive breast cancer stages (early, loco-regional and advanced). A payer perspective was used to calculate the absolute and relative direct costs of healthcare services associated with the treatment of HER2-positive breast cancer in the public and private healthcare systems. RESULTS: The number of women totaled 802 (early), 125 (loco-regional) and 218 (advanced). The mean age[SD] was 45[10], 46[10] and 48[10] years, respectively, while mean follow-up in all stages was approximately one year. Average costs of direct healthcare care in early, loco-regional and advanced stages were €11,796 (95%CI: €9,356-€12,498), €8,253 (95%CI: €6,843-€10,002), and €17,742 (95%CI: €15,720-€19,505), respectively. Trastuzumab accounted for the largest share of total costs in all three stages (range: 53–76%). CONCLUSION: Wherever comprehensive patient registries are infeasible or costly, real-world costs can be estimated through claims databases and data-mining strategies. Using this method, real-world costs have been estimated in Iran. The stage-specific cost estimates derived from this study can be used to perform real-world cost-effectiveness analyses of therapies for HER2-positive BC and support healthcare financing decisions. Public Library of Science 2018-10-01 /pmc/articles/PMC6166984/ /pubmed/30273393 http://dx.doi.org/10.1371/journal.pone.0205079 Text en © 2018 Ansaripour et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ansaripour, Amir
Zendehdel, Kazem
Tadayon, Niki
Sadeghi, Fatemeh
Uyl-de Groot, Carin A.
Redekop, W. Ken
Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
title Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
title_full Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
title_fullStr Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
title_full_unstemmed Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
title_short Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
title_sort use of data-mining to support real-world cost analyses: an example using her2-positive breast cancer in iran
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166984/
https://www.ncbi.nlm.nih.gov/pubmed/30273393
http://dx.doi.org/10.1371/journal.pone.0205079
work_keys_str_mv AT ansaripouramir useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran
AT zendehdelkazem useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran
AT tadayonniki useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran
AT sadeghifatemeh useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran
AT uyldegrootcarina useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran
AT redekopwken useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran